Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Bristol-Myers Squibb Co (BMY) Agrees To Extend Research With Five Prime Therapeutics Inc (FPRX)

Bristol-Myers Squibb Co (NYSE:BMY) has opted to extend the research term of its discovery collaboration agreement with Five Prime Therapeutics Inc (NASDAQ:FPRX). The two will continue working together towards the discovery, development, and commercialization of immuno-oncology therapies. The therapies are the target of three undisclosed immune checkpoint pathways.

There has been an existing collaboration since March 2014. However, its extension is expected to be more significant, according to Dr. Luis Borges, senior vice president of research at Five Prime.

In a press release, Borges said, “We are pleased that the demonstrated productivity of our unique research capabilities has prompted Bristol-Myers Squibb, a clear leader in immuno-oncology, to invest further in our efforts to find new drug candidates to modulate three checkpoint pathways.”

researching, researcher, research, medical, lab, health, electronic, technician, screen, specialist, woman, man, serious, studying, table, surgical glasses, practitioner, male,

wavebreakmedia/Shutterstock.com

The Extension Of The Research Term To Accommodate A Third Immune Checkpoint Pathway

The original collaboration agreement focused on two undisclosed immune checkpoint pathways. The collaboration has enabled Squibb to develop the first antibody to IND-enabling activities. With the new extension of the research term dated March 2017 to March 2018, the companies have now added a third immune checkpoint pathway. That means Bristol-Myers Squibb will provide funding for another 12 months. It will also obtain exclusive, global rights to develop and commercialize products directed towards certain protein targets.

Bristol-Myers Squibb Will Utilize Five Prime’s Discovery Capabilities

Bristol-Myers Squibb Co (NYSE:BMY) will top up another $11.6 million in research funding from the upfront fee of $20 million. The two will continue to work on antibody drug candidates targeting these three immuno-oncology programs. The pathways may be analyzed either as single agents or in amalgamation with approved therapies. Looking for more growth, Five Prime Therapeutics Inc (NASDAQ:FPRX) has also entered into strategic collaborations with various leading global pharmaceutical companies that have promising product candidates in clinical and late preclinical development.

Follow Bristol Myers Squibb Co (NYSE:BMY)
Trade (NYSE:BMY) Now!

Meanwhile, Bristol-Myers Squibb Co (NYSE:BMY)’s stock was trading at $59.14 a decline of $0.34 or 0.57%, while that of Five Prime Therapeutics Inc (NASDAQ:FPRX) closed at $51.05 an increase of $2.45 or 5.04%.

Follow Five Prime Therapeutics Inc (NASDAQ:FPRX)
Trade (NASDAQ:FPRX) Now!

Note: This article is written by Adam Russell and originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...